CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily. Although most studies have implicated CYP2C9 as the exclusive catalyst of hepatic tolbutamide hydroxylation in humans, there is evidence that other CYP2C enzymes (e.g., CYP2C19) may also participate. To that end, we used an immunochemical approach to assess the role of individual CYP2Cs in microsomal tolbutamide metabolism. Polyclonal antibodies were raised to CYP2C9 purified from human liver, and were then back-adsorbed against recombinant CYP2C19 coupled to a solid-phase support. Western blotting revealed that the absorbed anti-human CYP2C9 preparation reacted with only recombinant CYP2C9 and the corresponding native protein in hepatic microsomes, and no longer recognized CYP2C19 and CYP2C8. Monospecific anti-CYP2C9 not only retained the ability to inhibit CYP2C9-catalyzed reactions, as evidenced by its marked (90%) inhibition of diclofenac 4'-hydroxylation by purified CYP2C9 and by human liver microsomes, but also exhibited metabolic specificity, as indicated by its negligible (<15%) inhibitory effect on S-mephenytoin 4'-hydroxylation by purified CYP2C19 or hepatic microsomes containing CYP2C19. Monospecific anti-CYP2C9 was also found to inhibit rates of tolbutamide hydroxylation by 93 +/- 4 and 78 +/- 6% in CYP2C19-deficient and CYP2C19-containing human liver microsomes, respectively. Taken together, our results indicate that both CYP2C9 and CYP2C19 are involved in tolbutamide hydroxylation by human liver microsomes, and that CYP2C19 underlies at least 14 to 22% of tolbutamide metabolism. Although expression of CYP2C19 in human liver is less than that of CYP2C9, it may play an important role in tolbutamide disposition in subjects expressing either high levels of CYP2C19 or a catalytically deficient CYP2C9 enzyme.

[1]  F. Guengerich,et al.  Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. , 1987, The Journal of pharmacology and experimental therapeutics.

[2]  J. S. Miles,et al.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. , 1992, The Biochemical journal.

[3]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[4]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[5]  P. Srivastava,et al.  Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. , 1991, Molecular pharmacology.

[6]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[7]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[8]  T. Kronbach,et al.  Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. , 1985, Analytical biochemistry.

[9]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[10]  M. Romkes,et al.  Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. , 1991, Biochemistry.

[11]  J. P. Shea,et al.  A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450. , 1985, Analytical biochemistry.

[12]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. , 1986, The Journal of biological chemistry.

[13]  J. Lasker,et al.  Isolation of P450 enzymes from human liver. , 1991, Methods in enzymology.

[14]  T. Shimada,et al.  Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[15]  P. Poffenbarger,et al.  Pharmacogenetics of Tolbutamide Metabolism in Humans , 1978, Diabetes.

[16]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[17]  H. Yamazaki,et al.  Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.

[18]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[19]  T. Richardson,et al.  A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. , 1995, Archives of biochemistry and biophysics.

[20]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[21]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.